Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar).

Conclusion/Relevance: The results of this retrospective study suggest that BGlar resulted in similar glycemic outcomes compared with LGlar in a real-world setting and may be a preferable option in a value-based health care environment.
PMID: 32037850 [PubMed - as supplied by publisher]

Source: The Annals of Pharmacotherapy - February 9, 2020 Category: Drugs & Pharmacology Authors: Pitlick JM, Bryant GA, Daly MW, Koenigsfeld CF, Lehman N, Brueggen K, McCormick A, Wellington K Tags: Ann Pharmacother Source Type: research